Thomas Carmody, PhD

  • 7Articles
  • 28.3KReads1
  • 2005–2025Active
  • 79Collaborators
  • 87Citations2

About

Thomas Carmody, PhD, is affiliated with the University of Texas Southwestern Medical Center in Dallas, Texas. With publications spanning from 2005 to 2025, Carmody has contributed extensively to research on depression, addiction, child and adolescent psychiatry, and schizophrenia/schizoaffective disorders. His work includes studies on treatment-resistant depression, antidepressant efficacy, stimulant use disorder interventions, and psychometric evaluations of self-report scales. Carmody frequently collaborates with Madhukar H. Trivedi, A. John Rush, Chad D. Rethorst, Edward V. Nunes, and Manish K. Jha.

Publications

JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial
Original Research

Early Change in Depressive Symptom Severity with Naltrexone-Bupropion Combination and Its Association with Reduction in Methamphetamine Use: ADAPT-2 Trial

July 30, 2025

Improvement in depression accounted for approximately 25% of the treatment effect of naltrexone-bupropion on methamphetamine treatment response.
, , , et al
JCP
A Comparison of 3 Scales for Measuring Adolescent Depression
Original Research

A Comparison of 3 Scales for Measuring Adolescent Depression

December 18, 2023

Three patient-reported outcomes—Patient Health Questionnaire for Adolescents, Quick Inventory of Depressive Symptomatology–Self-Report, and Very Quick Inventory of Depressive Symptomatology–Self-Report—can assess depressive symptom severity and change over time. Scores on...
, , , et al
JCP
Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment
Original Research

Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment

June 27, 2022

The aim of this study was to develop and validate a categorical definition of “no meaningful benefit” from antidepressant treatment by equating percent change in scores on 3 common...
, , , et al
JCP
Original Research

CAST-SR Psychometrics in Stimulant Use Disorder

January 9, 2018

The self-report Concise Associated Symptoms Tracking Scale (CAST-SR) was designed to track symptoms such as mania and anxiety in depressed outpatients being treated with antidepressants. This study used data...
, , , et al
JCP
Original Research

Exercise vs Health Education for Treating Stimulant Use Disorder

February 14, 2017

Early evidence suggests that exercise may be an effective treatment approach for stimulant use disorders. Here, find out if exercise was superior to a health education intervention in reducing...
, , , et al
JCP
Original Research

A Trial of Compliance Therapy in Outpatients With Schizophrenia or Schizoaffective Disorder

August 15, 2005

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe